TCGA-A2-A25C-01A-11R-A169-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- PROTEIN_SECRETION+0.430
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.390
- INTERFERON_GAMMA_RESPONSE+0.380
- MITOTIC_SPINDLE+0.340
- ANDROGEN_RESPONSE+0.270
- ESTROGEN_RESPONSE_EARLY+0.270
- UV_RESPONSE_DN+0.250
- HEDGEHOG_SIGNALING+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- HYPOXIA-0.340
- OXIDATIVE_PHOSPHORYLATION-0.320
- XENOBIOTIC_METABOLISM-0.320
- CHOLESTEROL_HOMEOSTASIS-0.280
- COAGULATION-0.280
- GLYCOLYSIS-0.250
- IL6_JAK_STAT3_SIGNALING-0.250
- ADIPOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A26J-01A-11R-A169-07 | — | B | 0.881 |
| 2 | SRR650133 | — | — | 0.761 |
| 3 | TCGA-E2-A10A-01A-21R-A115-07 | — | B | 0.747 |
| 4 | SRR650203 | — | — | 0.735 |
| 5 | TCGA-B6-A1KN-01A-11R-A13Q-07 | — | C | 0.732 |
| 6 | TCGA-A7-A2KD-01A-31R-A21T-07 | — | C | 0.719 |
| 7 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.714 |
| 8 | MNG611 | — | — | 0.707 |
| 9 | TCGA-D8-A1JC-01A-11R-A13Q-07 | — | B | 0.704 |
| 10 | MDT-AP-3199 | Med | Medulloblastoma | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |